Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Atara Biotherapeutics, Inc. (ATRA)

Core Viewpoint - A securities class action lawsuit has been filed against Atara Biotherapeutics, alleging that the company failed to disclose significant manufacturing issues and deficiencies in its clinical study, which could negatively impact its regulatory approval and financial condition [1][2]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the Central District of California on behalf of individuals or entities that purchased Atara securities between May 20, 2024, and January 9, 2026 [1]. - The complaint claims that Atara's public statements were materially false and misleading due to undisclosed manufacturing issues and regulatory risks associated with its product tabelecleucel [2]. Group 2: Investor Information - Investors who acquired shares of Atara are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on May 22, 2026 [3]. - The firm provides contact information for interested investors to discuss their rights or interests regarding the class action [3].